138 related articles for article (PubMed ID: 24421449)
1. Erythropoiesis-Stimulating Agent (ESA) Practice Patterns in Patients With Chemotherapy-Induced Anemia (CIA) Treated at Hospital Oncology Clinics.
Reitan JF; van Breda A; Shreay S; Corey-Lisle PK; Cong Z
Hosp Pharm; 2013 Feb; 48(2):120-6. PubMed ID: 24421449
[TBL] [Abstract][Full Text] [Related]
2. Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.
Reitan JF; van Breda A; Corey-Lisle PK; Shreay S; Cong Z; Legg J
Clin Drug Investig; 2013 May; 33(5):383-9. PubMed ID: 23553358
[TBL] [Abstract][Full Text] [Related]
3. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
[TBL] [Abstract][Full Text] [Related]
4. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
5. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
Schwartzberg L; Burkes R; Mirtsching B; Rearden T; Silberstein P; Yee L; Inamoto A; Lillie T
BMC Cancer; 2010 Oct; 10():581. PubMed ID: 20973982
[TBL] [Abstract][Full Text] [Related]
6. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
[TBL] [Abstract][Full Text] [Related]
7. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
[TBL] [Abstract][Full Text] [Related]
8. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting.
Bernardo M; Crawford P; Hertel J; Sholer C; Xu X; Goss T; Kewalramani R; Globe D
J Manag Care Pharm; 2006; 12(9):714-25. PubMed ID: 17249904
[TBL] [Abstract][Full Text] [Related]
9. Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.
Hill JW; Shreay S; McGarvey N; De AP; Hess GP; Corey-Lisle PK
Support Care Cancer; 2013 Nov; 21(11):2957-65. PubMed ID: 23756616
[TBL] [Abstract][Full Text] [Related]
10. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
11. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Duh MS; Mody SH; McKenzie RS; Lefebvre P; Gosselin A; Bookhart BK; Piech CT
Drugs Aging; 2006; 23(12):969-76. PubMed ID: 17154661
[TBL] [Abstract][Full Text] [Related]
12. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
13. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
14. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
15. Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy.
McGarvey N; Xu H
J Health Econ Outcomes Res; 2016; 3(2):214-223. PubMed ID: 37663317
[No Abstract] [Full Text] [Related]
16. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
[TBL] [Abstract][Full Text] [Related]
17. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
18. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.
Kang RY; Lee J; Lee YH; Lee HS; Jeong JH; Lee YJ
Int J Clin Pharm; 2012 Aug; 34(4):651-7. PubMed ID: 22729393
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.
Hirsh V; Glaspy J; Mainwaring P; Manegold C; Ramlau R; Eid JE
Trials; 2007 Mar; 8():8. PubMed ID: 17341293
[TBL] [Abstract][Full Text] [Related]
20. Pharmacist collaborative practice agreement for the management of anemia in malignant disease with erythropoiesis-stimulating agents.
Weil E; Oxencis C
Support Care Cancer; 2015 Aug; 23(8):2507-13. PubMed ID: 25971214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]